Obermeyer Wood Investment Counsel Lllp Has $588,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Obermeyer Wood Investment Counsel Lllp decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 30.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,108 shares of the medical research company’s stock after selling 479 shares during the quarter. Obermeyer Wood Investment Counsel Lllp’s holdings in Thermo Fisher Scientific were worth $588,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Xponance Inc. increased its position in Thermo Fisher Scientific by 4.8% during the 4th quarter. Xponance Inc. now owns 76,761 shares of the medical research company’s stock worth $40,744,000 after buying an additional 3,487 shares during the period. AIA Group Ltd boosted its stake in shares of Thermo Fisher Scientific by 32.8% during the fourth quarter. AIA Group Ltd now owns 14,448 shares of the medical research company’s stock valued at $7,669,000 after purchasing an additional 3,568 shares in the last quarter. Integral Investment Advisors Inc. boosted its stake in shares of Thermo Fisher Scientific by 3.4% during the fourth quarter. Integral Investment Advisors Inc. now owns 1,388 shares of the medical research company’s stock valued at $737,000 after purchasing an additional 46 shares in the last quarter. Ninety One SA PTY Ltd boosted its stake in shares of Thermo Fisher Scientific by 5.9% during the fourth quarter. Ninety One SA PTY Ltd now owns 21,183 shares of the medical research company’s stock valued at $11,244,000 after purchasing an additional 1,179 shares in the last quarter. Finally, Peterson Wealth Services boosted its stake in shares of Thermo Fisher Scientific by 5.6% during the fourth quarter. Peterson Wealth Services now owns 6,616 shares of the medical research company’s stock valued at $3,512,000 after purchasing an additional 353 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,277 shares of company stock valued at $28,513,384. Insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Raymond James upped their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Finally, Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $604.69.

Thermo Fisher Scientific Trading Down 1.0 %

NYSE TMO traded down $5.47 on Thursday, hitting $541.78. The company’s stock had a trading volume of 2,075,782 shares, compared to its average volume of 1,547,352. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The company’s 50-day simple moving average is $571.57 and its 200 day simple moving average is $527.01. The firm has a market cap of $206.80 billion, a P/E ratio of 34.94, a PEG ratio of 2.33 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter last year, the business posted $5.40 EPS. The business’s revenue was down 4.9% on a year-over-year basis. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.